Manufactured drugs are developed with efficacy and precision in mind. Psychedelic medications on the other hand aren’t as reliable seeing as different people have different experiences using these drugs and additionally, using psychedelics sometimes is taxing on an individual’s body.
For this reason, many are now looking into synthetic psychedelics. However, it is unknown whether synthetic psychedelics will have as many consumers as plant-based medication has.
What is the difference between the two?
Well there’s the obvious one, natural psychedelics are plants grown and ingested as they are while synthetic psychedelics are laboratory made.
As the debate between the two alternatives grows, we can agree with psychedelics advocates about how important clinical studies have been on the study of the potential advantages of utilizing psilocybin mushrooms to treat mental health disorders such as anxiety, depression, addiction, substance abuse as well as post-traumatic stress disorder.
These studies have been the foundation on which the newly discovered potential of shrooms have been founded on and in the future, many are hopeful that there could be medications manufactured from psychedelic substances. There has also been almost no resistance from the health authorities’ front, with bodies like the FDA posing no threat to the advancement of these studies in relation to the various medicinal benefits of psilocybin mushrooms.
It should be noted that the determination to treat as well as manage these different disorders using synthetic psychedelics instead of the plant-based natural ones is partly so that the pharmaceutical industry can start paying more attention to this front.
The synthetic psychedelics drug development model may present an opportunity for the pharmaceutical industry to make profits, especially when it becomes legal to manufacture the said products. These products will control the medical development sector as they’ll be consistent as well as cost-effective which is ideal as compared to the unreliable results that organic psychedelics produce in different individuals.
However, the co-founder of Tabula Rasa Ventures, Marik Hazan, disagrees. He hypothesizes that a discussion on the potency of synthetic psychedelics as compared to plant-based psychedelics will gain traction as the conversation on synthetic compounds grows. He does not dispute that synthetic compounds are valuable as well as cost effective but doubts whether long-term backers of psychedelic therapy and treatments that are plant-based will be supportive of the synthetic compounds’ medical approach.
At the end of the day though, Hazan says the synthetic versus organic psychedelics debate will be worked out by the consumers and how they’ll respond to the psychedelic effects and efficacy of both models. Needless to say, they’ll be inclined to the more effective and desired psychedelic substance.
Entities like Pure Extract Technologies Inc. are likely to watch keenly as the psychedelic industry warms up to the benefits that synthetic hallucinogens offer beyond what organics can ever be.
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.